LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.27 -0.78

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.27

Max

1.29

Põhinäitajad
By Trading Economics
Sissetulek	17M -26M
Töötajad	171
EBITDA	19M -23M

Soovitused
By TipRanks
Soovitused	Müü
12 kuu keskmine prognoos	+53.85% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-27M 76M
Eelmine avamishind	2.05
Eelmine sulgemishind	1.27

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. märts 2026, 23:35 UTC

Uudisväärsed sündmused

Oil Prices Jump in Asia as U.S.-Iran Conflict Stokes Supply Fears -- Energy Comment

1. märts 2026, 23:49 UTC

Market Talk

Uudisväärsed sündmused

Australian Gold-Mining Stocks Rally as Attack on Iran Drives Gold Higher -- Market Talk

1. märts 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Gold, Silver Rise as Middle East Conflict Spurs Safe-Haven Demand -- Market Talk

1. märts 2026, 23:41 UTC

Market Talk

Uudisväärsed sündmused

Lasting Oil Price Shock Could Stoke Global Inflation -- Market Talk

1. märts 2026, 23:39 UTC

Market Talk

Uudisväärsed sündmused

Global Equities Roundup: Market Talk

1. märts 2026, 23:39 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Fall Amid Concerns About Higher Energy Prices -- Market Talk

1. märts 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Oil Jumps as Middle East Conflict Heightens Supply Disruption Concerns -- Market Talk

1. märts 2026, 23:24 UTC

Market Talk

Global Energy Roundup: Market Talk

1. märts 2026, 23:24 UTC

Market Talk

Financial Markets Trim Bets on RBA Hike in May -- Market Talk

1. märts 2026, 23:21 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. märts 2026, 23:21 UTC

Market Talk

Sky Network TV's Risk/Reward Still Not Attractive -- Market Talk

1. märts 2026, 23:19 UTC

Uudisväärsed sündmused

Front-Month Brent Crude Oil Futures Rose 8.5% to $79.08/bbl

1. märts 2026, 23:17 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rose 8.4% to $72.65/bbl

1. märts 2026, 23:14 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Extend Gains in Early Trade

1. märts 2026, 22:55 UTC

Uudisväärsed sündmused

Spot Gold Rises 1.9% to $5,278.61/oz Amid Middle East Conflict

1. märts 2026, 22:54 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rise Amid Middle East Conflict

1. märts 2026, 22:53 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rise 3.2% to $67.29/bbl

1. märts 2026, 22:38 UTC

Market Talk

Uudisväärsed sündmused

Attack on Iran Likely to Push Up Floor Under Gold -- Market Talk

1. märts 2026, 22:21 UTC

Tulu

Berkshire's Earnings Weren't as Bad as They Looked. A Goodwill Write-Down Hit Operating Profits. -- Barrons.com

1. märts 2026, 22:17 UTC

Market Talk

Financial Markets Trim Bets On RBA Hike In May -- Market Talk

1. märts 2026, 22:13 UTC

Market Talk

Uudisväärsed sündmused

OPEC+ Oil Output Boost Could Be Moot if Strait of Hormuz Unavailable -- Market Talk

1. märts 2026, 22:00 UTC

Market Talk

Uudisväärsed sündmused

Oil Could Surge Above $100 If Flows Don't Return to Normal Quickly -- Market Talk

1. märts 2026, 21:40 UTC

Market Talk

Uudisväärsed sündmused

Spot Gold Up as Investors Shield Against Risk -- Market Talk

1. märts 2026, 21:35 UTC

Market Talk

Uudisväärsed sündmused

Oil Prices Seen Rising to Low to Mid-US$80s Per Barrel -- Market Talk

1. märts 2026, 21:30 UTC

Market Talk

Australian Dollar Weakens Most as Trader Fear Long-Term Conflict -- Market Talk

1. märts 2026, 21:27 UTC

Market Talk

Uudisväärsed sündmused

Oil Prices Likely to Rise on Iran Conflict But to Manageable Levels -- Market Talk

1. märts 2026, 21:19 UTC

Market Talk

Uudisväärsed sündmused

Shipping Disruptions 'More Acute Risk' Than Oil Output From Iran Conflict -- Market Talk

1. märts 2026, 20:58 UTC

Market Talk

Uudisväärsed sündmused

Risk Off Stance in Markets Amid Fears of Wider Conflict -- Market Talk

1. märts 2026, 20:40 UTC

Market Talk

Australia Dollar to Fall Sharply Against U.S. Dollar on Middle East Conflict -- Market Talk

1. märts 2026, 20:24 UTC

Market Talk

Uudisväärsed sündmused

Brent Crude at $100/bbl Could Slow Pace of Global Rate Cuts -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

53.85% tõus

12 kuu keskmine prognoos

Keskmine 2 USD 53.85%

Kõrge 2 USD

Madal 2 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Müü

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.